Table 1. IC₅₀ Values for Evaluated Molecules Employing Doxorubicin as a Standard Drug^a.

		IC50 values (μM)
entry	compound	HepG2	MCF7	A549	MCF-10A
1	1	33.87 ± 3.34	39.76 ± 3.35	36.27 ± 3.37	NT
2	2	27.33 ± 3.87	29.39 ± 2.35	29.87 ± 3.05	NT
3	3	2.02 ± 0.15	1.61 ± 0.12	1.87 ± 0.32	77.29 ± 3.22
4	4a	13.74 ± 3.81	14.27 ± 2.05	14.87 ± 3.12	60.12 ± 2.31
5	4b	17.82 ± 2.04	18.76 ± 3.19	17.11 ± 3.17	58.12 ± 2.34
6	6	15.39 ± 3.12	15.21 ± 2.16	15.57 ± 2.94	57.02 ± 1.28
7	7	6.26 ± 0.32	5.60 ± 1.12	7.28 ± 1.34	78.54 ± 2.05
8	11	50.48 ± 3.16	60.10 ± 3.45	50.67 ± 3.23	NT
9	13	19.26 ± 2.07	18.09 ± 2.05	19.15 ± 3.88	51.57 ± 1.98
10	14	37.22 ± 1.45	39.33 ± 3.12	40.39 ± 3.15	NT
11	15	19.27 ± 2.06	19.27 ± 3.37	18.99 ± 3.45	52.33 ± 2.18
12	17	25.29 ± 1.34	29.02 ± 2.38	24.28 ± 3.88	NT
13	18	39.67 ± 1.22	45.62 ± 3.28	45.97 ± 3.65	NT
14	19	13.33 ± 1.96	15.21 ± 1.65	14.33 ± 1.96	60.45 ± 1.94
15	doxorubicin	2.71 ± 0.12	1.68 ± 0.11	2.22 ± 0.22	87.34 ± 1.47

^aThe percentage inhibition (IC₅₀) was determined from three successive tests utilizing an MTT procedure after 72 h of treatment. The statistics are reported as the mean standard deviation (S.D.). A standard drug is Doxorubicin. NT = Not Tested.